In Asian patients with lung cancer, about 30%–51.4% of lung adenocarcinoma patients have EGFR sensitive mutations3, 4, 5, 6 sensitive to epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI) therapy.7, 8, 9. This evidence concerns the gene EGFR and lung cancer.